Published • loading... • Updated
Bictegravir-Lenacapavir Combo Pill Earns FDA Approval in Suppressed HIV
The once-daily tablet combines bictegravir and lenacapavir and maintained viral suppression at 48 weeks in two Phase 3 trials, Gilead said.
- On Thursday, the U.S. Food and Drug Administration approved Gilead Sciences' Bixlenvo , the first once-daily single-tablet regimen for virologically suppressed HIV patients unable to use existing options.
- Many patients currently manage HIV with complex, multi-pill regimens due to drug resistance or intolerance, a challenge the ARTISTRY-1 trial specifically addressed by enrolling participants with a median age of 60 and extensive treatment histories.
- Phase 3 trials demonstrated comparable efficacy in maintaining viral suppression at 48 weeks, with the most common adverse reactions reported in at least 2% of participants being headache , nausea , and diarrhea .
- The pill carries a $4,595 list price for a 30-day supply; Gilead offers patient assistance and co-pay support programs, while trial participant Timothy Cameron said, "It's one less thing I'm putting in my body."
- Bixlenvo expands treatment choices rather than replacing Biktarvy within Gilead's broader HIV portfolio strategy. Chairman and Chief Executive Officer Daniel O'Day stated, "Today's approval could be the first of many in the years ahead.
Insights by Ground AI
14 Articles
14 Articles
The U.S. drug regulator has approved a new treatment for adults with HIV, which can be given once a day. The new option can replace treatment already used by patients who are controlled by the virus and can reduce the number of pills taken daily by those who follow more complicated regimens.
Bictegravir-Lenacapavir Combo Pill Earns FDA Approval in Suppressed HIV
(MedPage Today) -- The FDA approved the combination of bictegravir and lenacapavir (Bixlenvo) for adults with virologically suppressed HIV-1 infection, Gilead Sciences announced Thursday. The once-daily single tablet contains 75 mg of the integrase...
·New York, United States
Read Full Article
Bilxlenvo, the combination of bictegravir and lenacapavir is not approved by any regulatory authority outside the United States
·Los Angeles, United States
Read Full Article
Coverage Details
Total News Sources14
Leaning Left2Leaning Right2Center6Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 20%
C 60%
R 20%
Factuality
To view factuality data please Upgrade to Premium
